Compare Payoneer Global Inc (PAYO) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Payoneer Global Inc vs Viatris Inc — how do they compare? Payoneer Global Inc trades at $7.11 (market cap $2.42B), while Viatris Inc trades at $16.45 (market cap $19.09B). The key difference: Viatris Inc is far larger — about 7.9× Payoneer Global Inc's market cap, and Viatris Inc pays a 2.89% dividend while Payoneer Global Inc pays none. Which is the better fit depends on your goals.
| PAYO | VTRS | |
|---|---|---|
Market Cap | $2.42B | $19.09B |
Sector | Technology | Health |
52-Week High | $7.18 | $17.86 |
52-Week Low | $4.27 | $9.49 |
Enterprise Value | $2.16B | $31.21B |
Dividend Yield | — | 2.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Payoneer Global (PAYO) trades at $7.13, down 0.56% on the day, with a market cap of approximately $2.3 billion. The stock shows mixed technical signals with a bullish moving average trend but neutral oscillators. Fundamentally, revenue grew to $821 million in 2025 with a 79.4% gross margin, though net income margin declined to 5.83%. Recent news highlights the pending acquisition by Nuvei for $7.40 per share, with multiple law firms investigating the fairness of the deal price.
The acquisition offer at $7.40 provides near-term upside potential, but investor sentiment is cautious due to legal scrutiny. Long-term growth prospects remain positive with expanding global operations, though earnings volatility and competitive pressures present risks. Analyst consensus is bullish with 60% buy ratings, but the stock faces execution risks in integrating the India tech hub and maintaining B2B growth momentum.
Viatris (VTRS) trades at $16.61, down 1.6% on the day, with a bullish technical signal but mixed moving averages. The company reported Q2 2026 EPS of $0.69, beating estimates, and revenue growth of 5% year-over-year. Despite negative net income margins, strong cash flow generation supports dividends and buybacks. Recent news highlights pipeline progress and a higher 2026 outlook.
Outlook: Viatris shows operational strength with consistent earnings beats and cash flow, but high P/E and negative profitability pose risks. Investment opportunity lies in deleveraging and pipeline advancements, while headwinds include generic drug pricing pressure and regulatory uncertainty. Analyst sentiment is mixed with a hold-heavy consensus.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Payoneer Global Inc
Payoneer Global Inc is the world's go-to partner for digital commerce, everywhere. The company started as a cross-border payments platform that empowers businesses, online sellers, and freelancers. The platform allows the users to get paid in multiple currencies, bill global clients, and sell on marketplaces worldwide.
Read more on PAYO →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
